表紙
市場調查報告書

焦點市場分析:冠狀動脈疾病 (CAD)

Market Spotlight: Coronary Artery Disease

出版商 Datamonitor Healthcare 商品編碼 858317
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:冠狀動脈疾病 (CAD) Market Spotlight: Coronary Artery Disease
出版日期: 2020年08月17日內容資訊: 英文 50 Pages
簡介

在全球範圍內,冠狀動脈疾病(CAD)的患者人數預計將從2017年的3.279億增加到2026年的3.659億。男性在冠心病(CAD)患者中占主導地位。

本報告提供全球冠狀動脈疾病 (CAD) 治療藥市場相關調查分析,提供主要的上市·開發平台藥物,最近的趨勢和分析師的見解,臨床實驗,成功的概率,今後趨勢與法規趨勢,專利資訊,10年的發病率預測,許可證·收購交易,收益預測相關的系統性資訊。

概要

要點

疾病的背景

治療

  • 醫療管理
  • 醫療治療與手術
  • 心臟復健

流行病學

上市藥

開發平台藥物

最近的趨勢和分析師的見解

  • HeartFlow FFRCT
  • Virtue Sirolimus熔析球囊
  • MagicTouch SirolimusDCB
  • Biomatrix NeoFlex
  • Magmaris Resorbable Magnesium Scaffold
  • Orsiro

主要的法規趨勢

成功的概率

許可證·資產收購交易

母專利

商機

臨床實驗形勢

  • 贊助商:各狀況
  • 贊助商:不同階段
  • 最近的趨勢

參考文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0194778

Coronary artery disease (CAD), also called ischemic heart disease, occurs due to the narrowing of coronary arteries that supply oxygen-rich blood to the heart. A waxy substance called plaque builds up inside these arteries, leading to atherosclerosis. Plaque builds up within the coronary artery walls until the flow of oxygen-rich blood to the heart muscle is limited. This condition is also called ischemia, which may be chronic or acute. In chronic ischemia, the coronary artery narrows over time, limiting the blood flow to part of the heart muscle, while acute ischemia occurs due to a sudden rupture of plaque and formation of a blood clot. These blood clots can completely or mostly block the flow of blood through the artery, leading to acute myocardial ischemia, which further results in acute coronary syndromes. These include unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation MI (STEMI). If the oxygen-rich blood flow to the heart is blocked or reduced, heart attack or angina can occur.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 327.9 million prevalent cases of coronary artery disease worldwide, and forecasts that number to increase to 365.9 million prevalent cases by 2026.

Coronary artery disease has a male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 58.65% of cases aged 15 years and over were male. * Datamonitor Healthcare estimates that in 2017, there were approximately 9.5 million incident cases of acute coronary syndrome worldwide, and forecasts that number to increase to 10.7 million incident cases by 2026.

Acute coronary syndrome has a male predominance. Globally, Datamonitor Healthcare estimates that in 2017, 63.78% of cases aged 25 years and over were male.

The approved drugs in the coronary artery disease space target angiotensin converting enzyme (ACE), amyloid beta/amyloid plaques, adenosine diphosphate P2Y12 receptor, calcium channel, and coagulation factor X. The majority of marketed drugs are administered via the oral route, with one product being available in an intravenous formulation.

Industry-sponsored drugs in active clinical development for coronary artery disease are spread evenly across Phase I and Phase II.

Therapies in development for coronary artery disease focus on a variety of targets. These drugs are administered via the oral, subcutaneous, and percutaneous catheter/injection routes.

The only high-impact upcoming event for drugs in the coronary artery disease space is an expected CHMP opinion for Brilinta. The overall likelihood of approval of a Phase I cardiovascular disease asset is 6.8%, and the average probability a drug advances from Phase III is 54.2%. Drugs, on average, take 10.0 years from Phase I to approval in the overall cardiovascular space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for coronary artery disease have been in the late phases of development, with 51% of trials in Phase III-IV, and 49% in Phase I-II.

The US has a substantial lead in the number of coronary artery disease clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the coronary artery disease space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for coronary artery disease, with 98 trials.

Pfizer leads industry sponsors with the highest overall number of clinical trials for coronary artery disease.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Medical management
  • Medical procedures and surgery
  • Cardiac rehabilitation

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Brilinta for Coronary Artery Disease (September 1, 2019)
  • HeartFlow FFRCT for Coronary Artery Disease (June 17, 2019)
  • Virtue Sirolimus-Eluting Balloon for Coronary Artery Disease (June 13, 2019)
  • MagicTouch Sirolimus DCB for Coronary Artery Disease (April 30, 2019)
  • Biomatrix NeoFlex for Coronary Artery Disease (April 2, 2019)
  • Magmaris Resorbable Magnesium Scaffold for Coronary Artery Disease (March 5, 2019)
  • Orsiro for Coronary Artery Disease (March 3, 2019)
  • Brilinta for Coronary Artery Disease (February 25, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Brilinta Approved To Reduce Risk Of First MI, Stroke In High-Risk CAD Patients
  • Gadovist Approval Brings Contrast To Cardiac MRI

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Deals Shaping The Medical Industry, February 2020
  • Deals Shaping the Medical Industry, July 2019

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of coronary artery disease, 2017-26
  • Figure 2: Trends in incident cases of acute coronary syndrome, 2017-26
  • Figure 3: Overview of pipeline drugs for coronary artery disease in the US
  • Figure 4: Pipeline drugs for coronary artery disease, by company
  • Figure 5: Pipeline drugs for coronary artery disease, by drug type
  • Figure 6: Pipeline drugs for coronary artery disease, by classification
  • Figure 7: Brilinta for Coronary Artery Disease (September 1, 2019): Phase III - THEMIS
  • Figure 8: Brilinta for Coronary Artery Disease (September 1, 2019): Phase III - THEMIS
  • Figure 9: Biomatrix NeoFlex for Coronary Artery Disease (April 2, 2019): SORT-OUT VIII (Denmark)
  • Figure 10: Brilinta for Coronary Artery Disease (February 25, 2019): Phase III - THEMIS
  • Figure 11: Key upcoming events in coronary artery disease
  • Figure 12: Probability of success in the coronary artery disease pipeline
  • Figure 13: Clinical trials in coronary artery disease
  • Figure 14: Top 10 drugs for clinical trials in coronary artery disease
  • Figure 15: Top 10 companies for clinical trials in coronary artery disease
  • Figure 16: Trial locations in coronary artery disease
  • Figure 17: Coronary artery disease trials status
  • Figure 18: Coronary artery disease trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of coronary artery disease, 2017-26
  • Table 2: Prevalent cases of coronary artery disease, by gender, 2017
  • Table 3: Incident cases of acute coronary syndrome, 2017-26
  • Table 4: Incident cases of acute coronary syndrome, by gender, 2017
  • Table 5: Marketed drugs for coronary artery disease
  • Table 6: Pipeline drugs for coronary artery disease in the US
  • Table 7: Brilinta for Coronary Artery Disease (September 1, 2019)
  • Table 8: HeartFlow FFRCT for Coronary Artery Disease (June 17, 2019)
  • Table 9: Virtue Sirolimus-Eluting Balloon for Coronary Artery Disease (June 13, 2019)
  • Table 10: MagicTouch Sirolimus DCB for Coronary Artery Disease (April 30, 2019)
  • Table 11: Biomatrix NeoFlex for Coronary Artery Disease (April 2, 2019)
  • Table 12: Magmaris Resorbable Magnesium Scaffold for Coronary Artery Disease (March 5, 2019)
  • Table 13: Orsiro for Coronary Artery Disease (March 3, 2019)
  • Table 14: Brilinta for Coronary Artery Disease (February 25, 2019)
  • Table 15: Historical global sales, by drug ($m), 2015-19
  • Table 16: Forecasted global sales, by drug ($m), 2020-24